Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
28 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
22 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade
17 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s...
Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium
10 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital
03 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer
01 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300
21 mai 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
17 mai 2021 16h05 HE
|
Onconova Therapeutics, Inc.
Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical...
Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
22 avr. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova to Present at the Spring 2021 Oncology Investor Conference
29 mars 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...